Highlights

• Trajan Group Holdings Limited raises $90 million in an Initial Public Offering (IPO)
• Strong investor demand attracting top tier Australian, Asian, UK and NZ institutions
• 300+ employees participate via employee gift and ESOP, reflecting Trajan’s ‘people first’ culture
• Listing confirmed for 7th June 2021, 10.30am

Melbourne, Australia – Global analytical science and device company Trajan Group Holdings Limited (Trajan or the Company) has today announced it has successfully raised $90 million via an IPO and will list on the Australian Securities Exchange (ASX) on 7th June 2021.

Demand for shares significantly exceeded the size of the Offer, with strong participation from top tier institutional funds from Australia, Asia, UK, and NZ.

As well as raising $90m from external investors, Trajan undertook a unique Employee Gift Offer and ESOP to recognise and reward the contribution of staff. More than 300 Trajan employees will become stakeholders in the business upon Trajan listing on the ASX. Some staff were not eligible due to their country of residence.

Trajan Chief Executive Officer and Founder Mr. Stephen Tomisich said: “Sharing the Trajan story with the investment community in recent months has been exhilarating. The response is a strong validation of the substance and strength of the Trajan business today and its prospects for tomorrow. Being purpose-led, with a focus on delivering impact has brought us to this pivotal point in the Company’s journey. The potential of what comes next, driven by the same factors but with the backing of the broader investment community, is truly exciting.”

Trajan was founded in 2011 with the determination to build a scientific business that could deliver genuine impact and benefit people. Today, Trajan is a global success story with operations in Australia, Europe, US, and Asia, with four dedicated precision manufacturing facilities in Australia, Malaysia, and US, and a workforce of more than 450.

The Company is a global developer and manufacturer of analytical science instruments, devices, and solutions used in biological, food and environmental analysis. These areas of application reflect the Company’s strategy to impact human wellbeing. This is enabled by the delivery of precision products that protect the sample integrity and minimise result variation, leading to more informed decisions and treatments.

Trajan’s products are used across the analytical workflow and have broad life science applications including pharmaceutical, clinical diagnostics and pathology. The Company’s long-term customers and partners are global blue-chip companies including OEMs (Original Equipment Manufacturers), pharmaceutical companies and Contract Research Organisations.

Trajan has experienced significant growth and is expected to achieve revenue of $82.5m in FY22, 90% of which is generated through export markets.

Trajan is entering its next phase of growth with a deep technology commercialisation pipeline and globally identified acquisition targets, providing significant upside potential to the strong underlying existing consumable and components business. The Company has a strong acquisition record, having completed six complementary acquisitions which have all been self-funded. A seventh acquisition, MyHealthTest, was completed on 5th May 2021.

Trajan is led by founder and Chief Executive Officer Mr. Stephen Tomisich and Independent Non-Executive Chairman, Mr. John Eales.

The Offer (excluding the Employee Gift Offer, under which no proceeds will be raised) was fully underwritten by the Joint Lead Managers, Canaccord Genuity (Australia) Limited and Ord Minnett Limited. EY acted as Trajan’s financial adviser and DLA Piper provided legal advisory services.

About
Trajan is an Australian headquartered global developer and manufacturer of analytical and life sciences products and devices founded to have a positive impact on human wellbeing through scientific measurement. These products and solutions are used in the analysis of biological, food, water, and other environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Trajan is a global organisation of 450 people, with five manufacturing sites across the US, Australia, and Malaysia, and an operational footprint with operations in Australia, the US, Asia, and Europe.